Trial Profile
A Phase I Study to Determine the Maximum Tolerated Dose (MTD) of HK-001 and to Evaluate Its Pharmacokinetic Profile in Healthy Volunteers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Z-Butylidenephthalide (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Everfront Biotech
- 05 Sep 2023 Planned End Date changed from 1 Dec 2023 to 30 Jun 2025.
- 05 Sep 2023 Planned primary completion date changed from 1 Jun 2023 to 31 Dec 2024.
- 16 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2023.